Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors

0353545 - ÚEB 2011 RIV US eng P - Patentový dokument
Fuksová, Květa - Havlíček, Libor - Kryštof, Vladimír - Lenobel, René - Strnad, Miroslav
Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors.
Alexandria: United States Patent and Trademark Office, 2010. Vlastník: Ústav experimentální botaniky AV ČR, v. v. i., Univerzita Palackého v Olomouci. Datum podání přihlášky: 04.02.2005. Datum udělení patentu: 19.10.2010. Číslo patentu: US7816350
Grant CEP: GA ČR GA301/08/1649; GA AV ČR KAN200380801
Klíčová slova: Substituted [1,2,3]triazolo[4,5-D]pyrimidines * CDK * inhibitors
Kód oboru RIV: FD - Onkologie a hematologie
http://v3.espacenet.com/publicationDetails/originalDocument?FT=D&date=20101019&DB=EPODOC&locale=en_EP&CC=US&NR=7816350B2&KC=B2 http://arl-repository.lib.cas.cz/uloziste_av/UEB-Q/cav_un_epca-0353545_01.pdf

The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.
Trvalý link: http://hdl.handle.net/11104/0192775